| Symbol | ABCL |
|---|---|
| Name | ABCELLERA BIOLOGICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceuticals and Biotechnology |
| Address | 2215 YUKON STREET, VANCOUVER, British Columbia, V5Y 0A1, Canada |
| Telephone | +1 604 559-9005 |
| Fax | — |
| — | |
| Website | https://www.abcellera.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The companys AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners. Additional info from NASDAQ: |
Press Release: AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
Read moreAbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
Read morePress Release: AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
Read moreThermopylae Holdings Ltd. 🟢 acquired 38.0K shares of AbCellera Biologics Inc. (ABCL) at $3.44 Transaction Date: Feb 27, 2026 | Filing ID: 000004
Read moreBooth Andrew 🟢 acquired 42.6K shares of AbCellera Biologics Inc. (ABCL) at $3.42 Transaction Date: Feb 27, 2026 | Filing ID: 000004
Read more(30% Negative) Abcellera Biologics Inc (ABCL) Reports Q1 2026 Financial Results
Read moreNew Form S-8 - AbCellera Biologics Inc. <b>Filed:</b> 2026-02-24 <b>AccNo:</b> 0001703057-26-000013 <b>Size:</b> 820 KB
Read morePress Release: AbCellera to Present at Upcoming Investor Conferences in March and April 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04603651 | Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment o… | — | COVID-19 | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07108894 | A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Part… | Phase1 | Healthy Volunteers | Recruiting | 2025-07-25 | 2027-04-01 | ClinicalTrials.gov |
| NCT07118891 | Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause | Phase1 | Vasomotor Symptoms Associated With Menopause | Recruiting | 2025-06-23 | 2027-02-01 | ClinicalTrials.gov |
| NCT04701658 | A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Corona… | Phase2 | COVID-19 | Completed | 2021-02-01 | 2021-06-22 | ClinicalTrials.gov |
| NCT04634409 | A Study of Immune System Proteins in Participants With Mild to Moderate COVID-1… | Phase2 | COVID-19 | Completed | 2020-10-29 | 2021-10-18 | ClinicalTrials.gov |
| NCT04497987 | A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-C… | Phase3 | COVID-19 | Completed | 2020-08-02 | 2021-05-20 | ClinicalTrials.gov |
| NCT04427501 | A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With… | Phase2 | COVID-19 | Completed | 2020-06-17 | 2023-02-21 | ClinicalTrials.gov |
| NCT04411628 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | Phase1 | COVID-19 | Completed | 2020-05-28 | 2020-08-26 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | BIOLOGICAL | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| ABCL635 | BIOLOGICAL | Phase PHASE1 | Vasomotor Symptoms Associated With Menopause | RECRUITING | NCT07118891 |
| Placebo (Normal Saline 0.9%) | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07108894 |
| ABCL575 | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07108894 |